Royal London Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.8M | Sell |
903,602
-4,312
| -0.5% | -$251K | 0.11% | 160 |
|
|
2025
Q4 | $49M | Sell |
907,914
-12,853
| -1% | -$618K | 0.1% | 168 |
|
|
2025
Q3 | $41.5M | Sell |
920,767
-15,158
| -2% | -$708K | 0.09% | 192 |
|
|
2025
Q2 | $43.3M | Sell |
935,925
-17,446
| -2% | -$856K | 0.1% | 185 |
|
|
2025
Q1 | $58.1M | Sell |
953,371
-595,112
| -38% | -$34.7M | 0.14% | 137 |
|
|
2024
Q4 | $87.6M | Sell |
1,548,483
-372
| -0% | -$20.8K | 0.21% | 82 |
|
|
2024
Q3 | $80.1M | Buy |
1,548,855
+11,961
| +0.8% | +$561K | 0.2% | 96 |
|
|
2024
Q2 | $63.8M | Sell |
1,536,894
-166,286
| -10% | -$7.44M | 0.16% | 110 |
|
|
2024
Q1 | $92.4M | Buy |
1,703,180
+71,008
| +4% | +$3.62M | 0.23% | 84 |
|
|
2023
Q4 | $83.7M | Buy |
1,632,172
+43,204
| +3% | +$2.27M | 0.24% | 87 |
|
|
2023
Q3 | $92.3M | Buy |
1,588,968
+161,575
| +11% | +$9.9M | 0.3% | 68 |
|
|
2023
Q2 | $91.3M | Buy |
1,427,393
+227,724
| +19% | +$15.3M | 0.3% | 63 |
|
|
2023
Q1 | $83.1M | Buy |
1,199,669
+455,123
| +61% | +$32.1M | 0.33% | 59 |
|
|
2022
Q4 | $53.6M | Buy |
744,546
+13,093
| +2% | +$987K | 0.24% | 86 |
|
|
2022
Q3 | $52M | Sell |
731,453
-51,822
| -7% | -$3.76M | 0.26% | 75 |
|
|
2022
Q2 | $60.4M | Buy |
783,275
+2,600
| +0.3% | +$198K | 0.28% | 73 |
|
|
2022
Q1 | $57M | Buy |
780,675
+5,785
| +0.7% | +$388K | 0.22% | 89 |
|
|
2021
Q4 | $48.3M | Sell |
774,890
-21,604
| -3% | -$1.27M | 0.18% | 106 |
|
|
2021
Q3 | $47.1M | Sell |
796,494
-19,304
| -2% | -$1.27M | 0.19% | 105 |
|
|
2021
Q2 | $54.5M | Sell |
815,798
-37,880
| -4% | -$2.47M | 0.22% | 93 |
|
|
2021
Q1 | $53.9M | Buy |
853,678
+24,076
| +3% | +$1.5M | 0.25% | 91 |
|
|
2020
Q4 | $51.4M | Sell |
829,602
-39,780
| -5% | -$2.45M | 0.27% | 78 |
|
|
2020
Q3 | $52.1M | Sell |
869,382
-17,990
| -2% | -$1.08M | 0.32% | 70 |
|
|
2020
Q2 | $51.3M | Sell |
887,372
-39,932
| -4% | -$2.39M | 0.36% | 65 |
|
|
2020
Q1 | $50.5M | Sell |
927,304
-4,410
| -0.5% | -$270K | 0.41% | 57 |
|
|
2019
Q4 | $59.4M | Buy |
931,714
+286,360
| +44% | +$16.4M | 0.41% | 53 |
|
|
2019
Q3 | $32.7M | Sell |
645,354
-10,842
| -2% | -$510K | 0.25% | 93 |
|
|
2019
Q2 | $29.7M | Sell |
656,196
-11,173
| -2% | -$520K | 0.28% | 86 |
|
|
2019
Q1 | $31.8M | Sell |
667,369
-22,785
| -3% | -$1.13M | 0.25% | 94 |
|
|
2018
Q4 | $35.2M | Buy |
+690,154
| New | +$37.1M | 0.31% | 79 |
|
|
2018
Q3 | – | Sell |
-683,995
| Closed | -$37.9M | – | 527 |
|
|
2018
Q2 | $37.9M | Buy |
+683,995
| New | +$36.9M | 0.38% | 60 |
|
|
2016
Q2 | $41.4M | Sell |
562,663
-25,562,209
| -98% | -$1.81B | 0.68% | 32 |
|
|
2016
Q1 | $409K | Buy |
26,124,872
+25,524,410
| +4,251% | +$1.61B | 0.59% | 28 |
|
|
2015
Q4 | $41.8M | Buy |
600,462
+11,469
| +2% | +$758K | 0.64% | 34 |
|
|
2015
Q3 | $34.9M | Buy |
+588,993
| New | +$37.4M | 0.56% | 38 |
|
|
2014
Q4 | $311K | Buy |
523,499
+118,393
| +29% | +$6.68M | 0.59% | 40 |
|
|
2014
Q3 | $20.9M | Buy |
405,106
+20,927
| +5% | +$1.05M | 0.53% | 43 |
|
|
2014
Q2 | $19M | Sell |
384,179
-1,720
| -0.4% | -$84.8K | 0.44% | 51 |
|
|
2014
Q1 | $20.1M | Sell |
385,899
-10,860
| -3% | -$578K | 0.47% | 48 |
|
|
2013
Q4 | $22.3M | Buy |
396,759
+9,880
| +3% | +$503K | 0.57% | 39 |
|
|
2013
Q3 | $19.1M | Buy |
386,879
+4,342
| +1% | +$191K | 0.51% | 41 |
|
|
2013
Q2 | $17.7M | Buy |
+382,537
| New | +$16.6M | 0.52% | 37 |
|
Other funds holding BMY
VCM
VPM
Royal London Asset Management's BMY Position: Q1 2026 in Review
Royal London Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 0.47% in Q1 2026, selling an estimated $251K and leaving 903,602 shares worth $54.8M. The position accounts for 0.11% of the portfolio, ranked #160.
Royal London Asset Management first reported a position in BMY in Q2 2013 and has held it in 42 quarters since. The position peaked at $92.4M in Q1 2024. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Royal London Asset Management held 903,602 shares of Bristol-Myers Squibb worth $54.8M as of Q1 2026.
- Royal London Asset Management sold 4,312 Bristol-Myers Squibb shares in Q1 2026, an estimated $251K.
- Bristol-Myers Squibb made up 0.11% of Royal London Asset Management's portfolio in Q1 2026, its #160 holding.
- Royal London Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 42 quarters since.
- Royal London Asset Management's Bristol-Myers Squibb position peaked at $92.4M in Q1 2024.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.